Background NVX-CoV2373 is an adjuvanted, recombinant spike protein nanoparticle vaccine
that was shown to have clinical efficacy for the prevention of coronavirus disease 2019 (…

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

Importance Greater than 20% of cases and 0.4% of deaths from COVID-19 occur in children.
Following demonstration of the safety and efficacy of the adjuvanted, recombinant spike …

OBJECTIVE: When presenting with diabetic ketoacidosis (DKA), lean and obese patients
differ in their subsequent clinical course. Although lean patients tend to remain insulin …

Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and …

Background Safe and effective respiratory syncytial virus (RSV) vaccines remain elusive.
This was a phase I/II trial (NCT02927873) of ChAd155-RSV, an investigational chimpanzee …

PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein
COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and …

Questions remain regarding the effect of baseline host and exposure factors on vaccine
efficacy (VE) across pathogens and vaccine platforms. We report placebo-controlled data from …

BACKGROUND Over 20% of cases and 0.4% of deaths from Covid-19 occur in children.
Following demonstration of safety and efficacy of the adjuvanted, recombinant spike protein …

Background SARS-CoV-2 variants evade immunity despite vaccination with prototype COVID-19
vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating immune …